NovaGo Therapeutics
PrivateLast Round
Series B
Sep 2, 2026
Total Funding Raised
$41M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
NovaGo Therapeutics operates in Healthcare & Life Sciences and is based in Schlieren. Its latest recorded funding round was a Series B round in September 2026.
NovaGo Therapeutics is a biotechnology company that develops human antibody therapeutics to promote nerve growth and regeneration for conditions like spinal cord injury and stroke.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NovaGo Therapeutics Comparables
Compare NovaGo Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ReNetX Bio | 87% | |
| CSPC Pharmaceutical Group Limited | 77% | |
| Axonis Therapeutics | 77% |
For institutional investors. Book with your work email.
NovaGo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 2, 2026 | ||||
| Series A | Mar 4, 2019 | ||||
| Grant | Jan 1, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NovaGo Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Wings for Life Foundation | Series B |
| Wyss Zurich | Grant |
| Pureos Bioventures | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 2, 2026
$30M round led by Neurimmune AG and Pureos Bioventures.
- Aug 21, 2026
Monthly visitors grew 51% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 15, 2026
NovaGo Therapeutics AG is developing antibodies against Nogo-A to enable functional recovery by targeting a protein that inhibits nerve fiber regeneration and neuroplasticity, with CHF 24 million in Series B financing supporting a proof-of-concept study in patients with acute spinal cord injury in Switzerland in Sep '26.
- receives_awardSep 8, 2026
On Sep 8th '26, NovaGo Therapeutics AG is among three finalists for the prestigious Strüngmann Award 2025.
- is_developingSep 2, 2026
New funding supports NovaGo Therapeutics AG's continued development of its broader anti-Nogo-A pipeline, including applications in stroke and secondary progressive multiple sclerosis.
- receives_financingSep 2, 2026
NovaGo Therapeutics AG completes a $29.1M Series B financing round in Switzerland on Sep 2nd '26, led by Neurimmune and Pureos with participation from existing and new investors, to advance a proof-of-concept study in acute spinal cord injury.
For institutional investors. Book with your work email.
NovaGo Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NovaGo Therapeutics's valuation, stock price, and market status.
Is NovaGo Therapeutics a public or private company?
NovaGo Therapeutics is a private company.
What is the current stock price of NovaGo Therapeutics?
NovaGo Therapeutics is a private company, so its shares have no public market price. Caplight tracks NovaGo Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NovaGo Therapeutics worth (valuation)?
Valuation information for NovaGo Therapeutics is not publicly available.
Can I buy NovaGo Therapeutics stock?
NovaGo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NovaGo Therapeutics's last funding round?
NovaGo Therapeutics's most recent funding round was Series B on September 2, 2026.
Who are the main investors in NovaGo Therapeutics?
Key investors in NovaGo Therapeutics include Pureos Bioventures.
Will NovaGo Therapeutics IPO soon?
No public IPO plans have been announced for NovaGo Therapeutics.
How can I track NovaGo Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in NovaGo Therapeutics's shares on secondary markets.